pharmaphorum

MARCH 14, 2024

Cybin files a $150m placement on the back of new clinical data with its psychedelic drug CYB003 for depression and an FDA breakthrough designation.

FDA 94

FDA 94

pharmaphorum

AUGUST 21, 2022

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The post Axsome bounces back as FDA clears depression drug appeared first on. Photo by Sydney Sims on Unsplash.

FDA 88

FDA Marketing Pharma Sales 88

pharmaphorum

NOVEMBER 24, 2022

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up. Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments.

Sales 52

Sales Patients Competition Marketing 52

Pharma Marketing Network

JUNE 8, 2020

We are now in a 20-yearlong economic depression for the working and middle class as a result of health care prices inflating, prices not cost. Dave (HR): Yeah, I mean really everything we’re doing you know is about overturning the devastating effects of the status quo health plans. So that individuals can realize their full potential.

Healthcare 40

Healthcare Healthcare Marketing Pharma 40